To further examine the role of MDSCs in the anti-tumour effect of BTNL2 blockade, we depleted MDSCs in tumour-bearing mice using CD11b neutralizing antibodies, but did not utilize anti-Gr-1 mAb, as we detected CD8+ lymphocytes expressing Ly6C in the TME (Supplementary Fig. 5c). Here, BTNL2 is linked to neoplasm.